Given the unwanted side effects associated with generalised anti-angiogenesis therapies, directly inhibiting cancer cell CCL5 signaling to endothelial cells may constitute a novel strategy for blocking angiogenesis, tumor growth and spread in breast cancer. Here, CCL5 is linked to neoplasm.